Cointime

Aprea

company

About

Aprea focuses on the discovery and development of novel anticancer compounds reactivating the tumor suppressor protein p53.

  • 1 - 10

Highlights

Total Funding Amount
€96M
Funding Rounds
2
Investors
1

Details

Last Funding Type
Series C
Last Funding Money Raised
€50M
Industries
Biotechnology,Health Care,Medical,Personal Health,Pharmaceutical
Founded date
Jan 1, 2003
Number Of Employee
1 - 10
Operating Status
Active

Aprea is a Swedish biotech company focusing on the discovery and development of novel anticancer compounds reactivating the tumor suppressor protein p53. The Company's lead program, APR-246, is a first-in-class small molecule drug candidate in clinical development. Aprea's main shareholder is KDev Investments AB, an investment vehicle owned by Karolinska Development AB (Nasdaq Stockholm: KDEV) and Rosetta Capital Ltd. Other shareholders include Östersjöstiftelsen, Praktikerinvest, and KCIF Co-Investment Fund KB.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
€96M
Aprea has raised a total of €96M in funding over 2 rounds. Their latest funding was raised on Nov 30, 2018 from a Series C round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Nov 30, 2018 Series C €50M 1 — — Detail
Mar 9, 2016 Series B €46M 1 Versant Ventures — Detail

Investors

Number of Lead Investors
Number of Investors
1
1
Aprea is funded by 1 investors. Versant Ventures are the most recent investors.
Investor Name Lead Investor Funding Round
Versant Ventures — Series C
Cointime
Содержание
компания